search
Back to results

Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh (PROVIDE)

Primary Purpose

Rotavirus Diarrhea, Vaccine Virus Shedding, Tropical Enteropathy

Status
Completed
Phase
Phase 3
Locations
Bangladesh
Study Type
Interventional
Intervention
IPV
Rotarix
Sponsored by
University of Vermont
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Rotavirus Diarrhea focused on measuring Oral Vaccines, Vaccine Responsiveness, Tropical Enteropathy

Eligibility Criteria

undefined - 7 Days (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Mother willing to sign informed consent form.
  2. Healthy infant aged 0 to 7 days old.
  3. No obvious congenital abnormalities or birth defects.
  4. No abnormal (frequency and consistency) stools since birth.
  5. Stable household with no plans to leave the area for the next one year.

Exclusion Criteria:

  1. Parents are not willing to have child vaccinated at the field clinic.
  2. Parents are not willing to have child's blood drawn.
  3. Parents are planning to enroll child into another clinical study during the time period of this trial.
  4. Mother not willing to have blood drawn and breast milk extracted.
  5. Parents not willing to have field research assistant in home two times per week.
  6. History of seizures or other apparent neurologic disorders.
  7. Infant received any vaccines before start of study, except Bacillus Calmette-Guerin (BCG).
  8. Infant has any sibling currently or previously enrolled in this study, including a twin.

Sites / Locations

  • International Centre for Diarrhoeal Disease Research, Bangladesh

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

No Intervention

Experimental

Arm Label

Rotarix + No IPV

Rotarix + with IPV boost

No Rotarix + No IPV

No Rotarix + with IPV boost

Arm Description

Randomized to receive rotarix vaccine but no IPV boost

Randomized to receive both rotarix vaccine and IPV boost

Randomized to receive neither rotarix vaccine nor IPV boost

Randomized to receive no rotarix vaccine but to receive IPV boost

Outcomes

Primary Outcome Measures

Presence of fecal shedding of polio vaccine virus determined by culture (polio trial)
One or more episodes of rotavirus-associated diarrhea (rotavirus trial)

Secondary Outcome Measures

Duration of fecal shedding of polio vaccine virus (polio trial)
Community fecal shedding of polio vaccine virus just prior to one year OPV dose (polio trial)
Presence and duration of fecal polio virus shedding within the three individual virus strains (polio trial)
Serum neutralizing antibody response (polio trial)
Total number of diarrheal episodes (rotavirus trial)
Total duration of rotavirus-associated diarrheal episodes (rotavirus trial)

Full Information

First Posted
June 3, 2011
Last Updated
April 13, 2015
Sponsor
University of Vermont
Collaborators
Bill and Melinda Gates Foundation, University of Virginia, International Centre for Diarrhoeal Disease Research, Bangladesh, Washington University School of Medicine, Stanford University, Centers for Disease Control and Prevention
search

1. Study Identification

Unique Protocol Identification Number
NCT01375647
Brief Title
Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh
Acronym
PROVIDE
Official Title
Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh
Study Type
Interventional

2. Study Status

Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
May 2011 (undefined)
Primary Completion Date
October 2014 (Actual)
Study Completion Date
November 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Vermont
Collaborators
Bill and Melinda Gates Foundation, University of Virginia, International Centre for Diarrhoeal Disease Research, Bangladesh, Washington University School of Medicine, Stanford University, Centers for Disease Control and Prevention

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Oral polio and rotavirus vaccines are significantly less effective in children living in the developing world. Tropical enteropathy, which is associated with intestinal inflammation, decreased absorption and increased permeability, may contribute substantially to oral vaccine failure in developing country settings. Other possible causes of oral vaccine underperformance include malnutrition, interference with maternal or breastmilk antibodies, changes in gut microbiota, and genetic susceptibility. Primary Objective: to determine whether tropical enteropathy impairs the efficacy of oral polio and rotavirus vaccines in children in Bangladesh. Secondary Objectives: 1) to determine the impact of an inactivated polio vaccine (IPV) boost on the efficacy of oral polio vaccine and 2) to determine the efficacy of oral rotavirus vaccine to prevent rotavirus diarrhea The polio and rotavirus randomized clinical trials are embedded as secondary objectives within the exploratory study of tropical enteropathy. The primary and secondary outcome measures are relevant to the randomized clinical trials.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rotavirus Diarrhea, Vaccine Virus Shedding, Tropical Enteropathy
Keywords
Oral Vaccines, Vaccine Responsiveness, Tropical Enteropathy

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Factorial Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
700 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Rotarix + No IPV
Arm Type
Experimental
Arm Description
Randomized to receive rotarix vaccine but no IPV boost
Arm Title
Rotarix + with IPV boost
Arm Type
Experimental
Arm Description
Randomized to receive both rotarix vaccine and IPV boost
Arm Title
No Rotarix + No IPV
Arm Type
No Intervention
Arm Description
Randomized to receive neither rotarix vaccine nor IPV boost
Arm Title
No Rotarix + with IPV boost
Arm Type
Experimental
Arm Description
Randomized to receive no rotarix vaccine but to receive IPV boost
Intervention Type
Biological
Intervention Name(s)
IPV
Intervention Description
Administered per protocol
Intervention Type
Biological
Intervention Name(s)
Rotarix
Intervention Description
Administered per protocol
Primary Outcome Measure Information:
Title
Presence of fecal shedding of polio vaccine virus determined by culture (polio trial)
Time Frame
25 days following week 52 visit
Title
One or more episodes of rotavirus-associated diarrhea (rotavirus trial)
Time Frame
Birth to one year
Secondary Outcome Measure Information:
Title
Duration of fecal shedding of polio vaccine virus (polio trial)
Time Frame
25 days following week 52 visit
Title
Community fecal shedding of polio vaccine virus just prior to one year OPV dose (polio trial)
Time Frame
52 weeks
Title
Presence and duration of fecal polio virus shedding within the three individual virus strains (polio trial)
Time Frame
25 days following week 52 visit
Title
Serum neutralizing antibody response (polio trial)
Time Frame
40 weeks and 53 weeks
Title
Total number of diarrheal episodes (rotavirus trial)
Time Frame
Birth to one year
Title
Total duration of rotavirus-associated diarrheal episodes (rotavirus trial)
Time Frame
Birth to one year

10. Eligibility

Sex
All
Maximum Age & Unit of Time
7 Days
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Mother willing to sign informed consent form. Healthy infant aged 0 to 7 days old. No obvious congenital abnormalities or birth defects. No abnormal (frequency and consistency) stools since birth. Stable household with no plans to leave the area for the next one year. Exclusion Criteria: Parents are not willing to have child vaccinated at the field clinic. Parents are not willing to have child's blood drawn. Parents are planning to enroll child into another clinical study during the time period of this trial. Mother not willing to have blood drawn and breast milk extracted. Parents not willing to have field research assistant in home two times per week. History of seizures or other apparent neurologic disorders. Infant received any vaccines before start of study, except Bacillus Calmette-Guerin (BCG). Infant has any sibling currently or previously enrolled in this study, including a twin.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Beth Kirkpatrick, M.D.
Organizational Affiliation
University of Vermont
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
William Petri, M.D., Ph.D.
Organizational Affiliation
University of Virginia School of Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Rashidul Haque, M.D., Ph.D.
Organizational Affiliation
International Center for Diarrhoeal Disease Research, Bangladesh
Official's Role
Principal Investigator
Facility Information:
Facility Name
International Centre for Diarrhoeal Disease Research, Bangladesh
City
Dhaka
Country
Bangladesh

12. IPD Sharing Statement

Citations:
PubMed Identifier
25711607
Citation
Kirkpatrick BD, Colgate ER, Mychaleckyj JC, Haque R, Dickson DM, Carmolli MP, Nayak U, Taniuchi M, Naylor C, Qadri F, Ma JZ, Alam M, Walsh MC, Diehl SA; PROVIDE Study Teams; Petri WA Jr. The "Performance of Rotavirus and Oral Polio Vaccines in Developing Countries" (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems. Am J Trop Med Hyg. 2015 Apr;92(4):744-51. doi: 10.4269/ajtmh.14-0518. Epub 2015 Feb 23.
Results Reference
background
PubMed Identifier
34565452
Citation
Kupkova K, Shetty SJ, Haque R, Petri WA Jr, Auble DT. Histone H3 lysine 27 acetylation profile undergoes two global shifts in undernourished children and suggests altered one-carbon metabolism. Clin Epigenetics. 2021 Sep 26;13(1):182. doi: 10.1186/s13148-021-01173-8.
Results Reference
derived
PubMed Identifier
32867719
Citation
Lin Y, Zhou J, Kumar S, Xie W, G Jensen SK, Haque R, Nelson CA, Petri WA Jr, Ma JZ. Group penalized generalized estimating equation for correlated event-related potentials and biomarker selection. BMC Med Res Methodol. 2020 Aug 31;20(1):221. doi: 10.1186/s12874-020-01103-x.
Results Reference
derived
PubMed Identifier
32157282
Citation
Williams FB, Kader A, Colgate ER, Dickson DM, Carmolli M, Uddin MI, Sharmin S, Islam S, Bhuiyan TR, Alam M, Nayak U, Mychaleckyj JC, Petri WA, Haque R, Qadri F, Kirkpatrick BD, Lee B. Maternal Secretor Status Affects Oral Rotavirus Vaccine Response in Breastfed Infants in Bangladesh. J Infect Dis. 2021 Oct 13;224(7):1147-1151. doi: 10.1093/infdis/jiaa101.
Results Reference
derived
PubMed Identifier
29514306
Citation
Rogawski ET, Platts-Mills JA, Colgate ER, Haque R, Zaman K, Petri WA, Kirkpatrick BD. Quantifying the Impact of Natural Immunity on Rotavirus Vaccine Efficacy Estimates: A Clinical Trial in Dhaka, Bangladesh (PROVIDE) and a Simulation Study. J Infect Dis. 2018 Mar 5;217(6):861-868. doi: 10.1093/infdis/jix668.
Results Reference
derived
PubMed Identifier
29394355
Citation
Lee B, Carmolli M, Dickson DM, Colgate ER, Diehl SA, Uddin MI, Islam S, Hossain M, Rafique TA, Bhuiyan TR, Alam M, Nayak U, Mychaleckyj JC, McNeal MM, Petri WA, Qadri F, Haque R, Kirkpatrick BD. Rotavirus-Specific Immunoglobulin A Responses Are Impaired and Serve as a Suboptimal Correlate of Protection Among Infants in Bangladesh. Clin Infect Dis. 2018 Jul 2;67(2):186-192. doi: 10.1093/cid/ciy076.
Results Reference
derived
PubMed Identifier
29390150
Citation
Lee B, Dickson DM, deCamp AC, Ross Colgate E, Diehl SA, Uddin MI, Sharmin S, Islam S, Bhuiyan TR, Alam M, Nayak U, Mychaleckyj JC, Taniuchi M, Petri WA Jr, Haque R, Qadri F, Kirkpatrick BD. Histo-Blood Group Antigen Phenotype Determines Susceptibility to Genotype-Specific Rotavirus Infections and Impacts Measures of Rotavirus Vaccine Efficacy. J Infect Dis. 2018 Apr 11;217(9):1399-1407. doi: 10.1093/infdis/jiy054. Erratum In: J Infect Dis. 2018 Jun 5;218(1):171-172.
Results Reference
derived
PubMed Identifier
28444240
Citation
Upfill-Brown A, Taniuchi M, Platts-Mills JA, Kirkpatrick B, Burgess SL, Oberste MS, Weldon W, Houpt E, Haque R, Zaman K, Petri WA Jr. Nonspecific Effects of Oral Polio Vaccine on Diarrheal Burden and Etiology Among Bangladeshi Infants. Clin Infect Dis. 2017 Aug 1;65(3):414-419. doi: 10.1093/cid/cix354.
Results Reference
derived
PubMed Identifier
28293424
Citation
Lu M, Zhou J, Naylor C, Kirkpatrick BD, Haque R, Petri WA Jr, Ma JZ. Application of penalized linear regression methods to the selection of environmental enteropathy biomarkers. Biomark Res. 2017 Mar 9;5:9. doi: 10.1186/s40364-017-0089-4. eCollection 2017.
Results Reference
derived
PubMed Identifier
27217217
Citation
Colgate ER, Haque R, Dickson DM, Carmolli MP, Mychaleckyj JC, Nayak U, Qadri F, Alam M, Walsh MC, Diehl SA, Zaman K, Petri WA, Kirkpatrick BD. Delayed Dosing of Oral Rotavirus Vaccine Demonstrates Decreased Risk of Rotavirus Gastroenteritis Associated With Serum Zinc: A Randomized Controlled Trial. Clin Infect Dis. 2016 Sep 1;63(5):634-41. doi: 10.1093/cid/ciw346. Epub 2016 May 23.
Results Reference
derived
PubMed Identifier
27154394
Citation
Taniuchi M, Platts-Mills JA, Begum S, Uddin MJ, Sobuz SU, Liu J, Kirkpatrick BD, Colgate ER, Carmolli MP, Dickson DM, Nayak U, Haque R, Petri WA Jr, Houpt ER. Impact of enterovirus and other enteric pathogens on oral polio and rotavirus vaccine performance in Bangladeshi infants. Vaccine. 2016 Jun 8;34(27):3068-3075. doi: 10.1016/j.vaccine.2016.04.080. Epub 2016 May 3.
Results Reference
derived
PubMed Identifier
26870801
Citation
Naylor C, Lu M, Haque R, Mondal D, Buonomo E, Nayak U, Mychaleckyj JC, Kirkpatrick B, Colgate R, Carmolli M, Dickson D, van der Klis F, Weldon W, Steven Oberste M; PROVIDE study teams; Ma JZ, Petri WA Jr. Environmental Enteropathy, Oral Vaccine Failure and Growth Faltering in Infants in Bangladesh. EBioMedicine. 2015 Sep 25;2(11):1759-66. doi: 10.1016/j.ebiom.2015.09.036. eCollection 2015 Nov.
Results Reference
derived
PubMed Identifier
26643930
Citation
Mychaleckyj JC, Haque R, Carmolli M, Zhang D, Colgate ER, Nayak U, Taniuchi M, Dickson D, Weldon WC, Oberste MS, Zaman K, Houpt ER, Alam M, Kirkpatrick BD, Petri WA Jr. Effect of substituting IPV for tOPV on immunity to poliovirus in Bangladeshi infants: An open-label randomized controlled trial. Vaccine. 2016 Jan 12;34(3):358-66. doi: 10.1016/j.vaccine.2015.11.046. Epub 2015 Nov 28.
Results Reference
derived

Learn more about this trial

Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh

We'll reach out to this number within 24 hrs